Paul Hartmann AGSTU:PHH2 +0.49%61 EBITDA Margin % is 13.16% as of Dec. 2025, which is 33% above its 10-year median of 9.90. GuruFocus rates STU:PHH2 with a GF Score™ of 61/100 and a GF Value™ of €229.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 54.66% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Paul Hartmann AG's EBITDA for the
six
months ended in Dec. 2025 was €163 Mil. Paul Hartmann AG's Revenue for the
six
months ended in Dec. 2025 was €1,236 Mil. Therefore, Paul Hartmann AG's EBITDA margin for the quarter that ended in Dec. 2025 was 13.16%.
Paul Hartmann AG (STU:PHH2) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Paul Hartmann AG EBITDA Margin % Related Terms
Paul Hartmann AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PHH2 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (STU:PHH2) has a EBITDA Margin % of 13.16% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Paul Hartmann AG and its competitors. This is 33% above median its historical median of 9.90. Over the past decade, Paul Hartmann AG's EBITDA Margin % has ranged from 7.13 to 12.76. According to the industry distribution chart, Paul Hartmann AG ranks #370 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 45.3%.
Is Paul Hartmann AG's EBITDA Margin % too high?
Paul Hartmann AG's current EBITDA Margin % of 13.16% is 33% above median its 10-year median of 9.90. Over the past 10 years, this metric has ranged from a low of 7.13 to a high of 12.76. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Paul Hartmann AG's value of 13.16% is 76.1% above this industry median. Based on the distribution chart, Paul Hartmann AG ranks #370 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #370 out of 816 companies for EBITDA Margin %. This puts Paul Hartmann AG in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Paul Hartmann AG's value of 13.16% is 76.1% above this benchmark. Historically, Paul Hartmann AG's own EBITDA Margin % has ranged from 7.13 to 12.76 over the past decade. While the company's 10-year median is 9.90 vs. the industry median of 7.48, Paul Hartmann AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current EBITDA Margin % of 13.16% is 76.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current EBITDA Margin % is 13.16%, which is 33% above median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Fairly Valued. The stock's GF Value™ is €229.60, compared to a current price of €205.00 — trading 10.7% below its estimated fair value. The current EBITDA Margin % is 13.16%, which is 33% above median its 10-year median of 9.90 and 76.1% above the Medical Devices & Instruments industry median of 7.48. Paul Hartmann AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current EBITDA Margin % is 13.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €205.00 is trading 10.7% below its estimated GF Value™ of €229.60.
GuruFocus considers Paul Hartmann AG to be Fairly Valued.
Key valuation signals for STU:PHH2:
EBITDA Margin %: 13.16% (33% above median its 10-year median of 9.90)
GF Value™: €229.60 vs. price of €205.00 (10.7% below fair value)
Industry Position: 76.1% above the Medical Devices & Instruments median (#370 of 816)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
61GF Score
Get the complete analysis for STU:PHH2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
